Collaboration advances personalised mRNA-based CRISPR therapy
A close partnership between academic institutions, industry, and the FDA is necessary for success in manufacturing personalised treatment. That’s a key message behind a talk at BPI this week, presented by Max Sellman of Aldevron. The post Collaboration Key to First Personalised mRNA-based CRISPR Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
- Published by
- GEN — Genetic Engineering & Biotechnology News
- Evidence type
- Industry
GEN reports: A close partnership between academic institutions, industry, and the FDA is necessary for success in manufacturing personalised treatment. That’s a key message behind a talk at BPI this week, presented by Max Sellman of Aldevron. The post Collaboration Key to First Personalised mRNA-based CRISPR Therapy appeared first on GEN - Genetic Engineering and Biotechnology News.
The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit. Consult the linked GEN report for the source organisation’s full announcement.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call